To the Editor-Pneumocystis jirovecii is a well-described opportunistic pathogen in human immunodeficiency virus (HIV) infection, but it is less commonly associated with pneumonia in other states of immunocompromise. However, outbreaks of P. jirovecii pneumonia (PCP) have been described in renal transplant recipients in both Europe and Asia [1] [2] [3] . Explanations for this, including the possible modes of transmission, have not been established, and risk factors for the development of PCP remain poorly understood. However, policies relating to immunosuppression and HLA matching have changed in recent years [4] , and PCP prophylaxis guidance in renal transplant recipients has a poor evidence base [5] .
We write to draw attention to the preliminary results of investigation of 2 concurrent outbreaks of PCP in renal transplant recipients in the Northwest [6] of available samples has shown that a different clonal genotype predominates in each hospital, suggesting that person-to-person transmission or environmental exposure may have occurred within these units (Table 1) .
This now constitutes the largest combined cluster of cases of PCP in renal transplant recipients in the world, and prompted us to circulate a brief questionnaire to 66 renal units in the United Kingdom, in November 2010. Replies were received from 36 units (55%), revealing that, since 2008, 16 units (44.4%) had treated renal transplant recipients for PCP and 8 (22.2%) had also seen cases in nontransplant recipients receiving immunosuppression. A quarter of all units have experienced an increase in the incidence of PCP. Between 2008 and 2010, 79 cases were reported, compared with 28 in the same units in the previous 10 years (1998-2007), a nearly 10-fold increase. The mortality rate has remained constant at 21.5%.
In conclusion, there has been an unexplained increase in PCP among renal transplant recipients throughout the United Kingdom, and our results suggest that different genotypes are involved in local clonal outbreaks. Further studies are needed to reassess the risk factors for the development of PCP in these patients as well as an urgent reconsideration about the type and duration of chemoprophylaxis used. NOTE. Genotypic Sequencing of ITS1 and mt26S [6] . RLUH, Royal Liverpool University Hospital; SRH, Salford Royal Hospital.
